Clinical TrialsThe Phase III VELA program concluded its recruitment phase with 800 patients approximately 40% faster than the industry average, indicating strong momentum.
Efficacy And SafetySonelokimab's strong anti-inflammatory activity should be a big differentiator from currently available biologics.
Market PotentialThe level of efficacy, combined with dosing convenience, fast onset, a safe/tolerable profile, and a comprehensive label would position SLK to effectively compete in the growing HS market expected to reach $10B-$15B by 2035.